![Nicholas Benedict](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nicholas Benedict
Founder at
Vaderis Therapeutics AG
Profile
Nicholas Benedict is the founder of Allecra Therapeutics SAS, founded in 2013.
Mr. Benedict was the founder of Allecra Therapeutics GmbH, founded in 2013, and served as Chief Executive Officer from 2013 to 2018.
Mr. Benedict is also the founder of Vaderis Therapeutics AG.
Former job at Lumavita AG as Chief Executive Officer from 2008 to 2009.
Former job at Novartis Corp.
as Chief Operating Officer.
Former job at Basilea Pharmaceutica AG as Chief Business Officer.
Former job at Archimedes Pharma Ltd. as Executive Vice President & Head-Europe.
Education includes an MBA from The University of Manchester and an undergraduate degree from King's College London.
Nicholas Benedict active positions
| Companies | Position | Start |
|---|---|---|
Vaderis Therapeutics AG
 Vaderis Therapeutics AG BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops targeted therapies for rare diseases associated with vascular malformations | Founder | - |
Former positions of Nicholas Benedict
| Companies | Position | End |
|---|---|---|
Allecra Therapeutics GmbH
 Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which manufactures pharmaceuticals to combat multi drug-resistant bacterial infections | Chief Executive Officer | 23/08/2018 |
Allecra Therapeutics SAS
 Allecra Therapeutics SAS Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel therapies to combat antibiotic resistance | Founder | - |
Archimedes Pharma Ltd.
 Archimedes Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of chronic and debilitating illnesses | Corporate Officer/Principal | - |
| BASILEA PHARMACEUTICA AG | Corporate Officer/Principal | - |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmacitical products | Chief Operating Officer | - |
Training of Nicholas Benedict
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
13
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmacitical products | Health Technology |
The University of Manchester
 The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Basilea Pharmaceutica AG
 Basilea Pharmaceutica AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Archimedes Pharma Ltd.
Archimedes Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of chronic and debilitating illnesses | Health Technology |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lumavita AG
 Lumavita AG Medical/Nursing ServicesHealth Services Develops and commercializes antiinfectives for women's health | Health Services |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which manufactures pharmaceuticals to combat multi drug-resistant bacterial infections | Health Technology |
Vaderis Therapeutics AG
Vaderis Therapeutics AG BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops targeted therapies for rare diseases associated with vascular malformations | Health Technology |
Allecra Therapeutics SAS
Allecra Therapeutics SAS Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel therapies to combat antibiotic resistance | Health Technology |
- Stock Market
- Insiders
- Nicholas Benedict
